The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Iunilaĭnen O.A.

FGBU "ndokrinologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii

Starostina E.G.

FGUZ "Moskovskiĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut (MONIKI) im. M.F. Vladimirskogo"

Dzeranova L.K.

ndokrinologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Kudryashkina G.N.

Psychiatric City Hospital №1, Moscow, Russia

Kesselman L.G.

Psychiatric City Hospital №1, Moscow, Russia

Baranov P.A.

Russian Medical Academy of Postgraduate Education, Moscow, Russia

Dedov I.I.

Endocrinology Research Centre

Hyperprolactinemia associated with neuroleptic treatment: clinical characteristics and an impact on sexual function

Authors:

Iunilaĭnen O.A., Starostina E.G., Dzeranova L.K., Kudryashkina G.N., Kesselman L.G., Baranov P.A., Dedov I.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(11): 17‑25

DOI: 10.17116/jnevro201611611117-25

Views: 2531

Downloaded: 59

Download PDF (RU)
Contact the author
Table of contents

HYPERPROLACTINEMIA ASSOCIATED WITH NEUROLEPTIC TREATMENT: CLINICAL CHARACTERISTICS AND AN IMPACT ON SEXUAL FUNCTION
HYPERPROLACTINEMIA ASSOCIATED WITH NEUROLEPTIC TREATMENT: CLINICAL CHARACTERISTICS AND AN IMPACT ON SEXUAL FUNCTION

To cite this article:

Iunilaĭnen OA, Starostina EG, Dzeranova LK, Kudryashkina GN, Kesselman LG, Baranov PA, Dedov II. Hyperprolactinemia associated with neuroleptic treatment: clinical characteristics and an impact on sexual function. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(11):17‑25. (In Russ.)
https://doi.org/10.17116/jnevro201611611117-25

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
 
МСФ на ЯМ
Close metadata
Recommended articles:
Controversial issues of diagnosis and theoretical concepts of schi­zophrenia in childhood. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):17-24
Psychological concepts — design of clinical models of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):25-31
Pharmacotherapy of schi­zophrenia: clinical and some age-related aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):41-50
Clinical systematics of chro­nic delu­sional psychoses in schi­zophrenia and schi­zophrenia-spectrum pathology. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):65-74
Prolonged and chro­nic endo­genous manic and manic-delusional states (psychopathology, typo­logy, dyna­mics, clinic). S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):75-81
Mela­tonergic anti­depressant agomelatine: augmentation of anti­psychotic drugs in treatment of post-schizophrenic depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):5-12
Meta­bolic syndrome in clinical psychiatric practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):13-20
Poly­morphic variants in the cluster of genes enco­ding trace amine rece­ptors and cognitive functioning in patients with schi­zophrenia spectrum diso­rders and healthy controls. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):122-128
The rela­tionship between inflammatory markers, fati­gue, and effort-based deci­sion-making in patients at clinical high risk for psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):85-91
Diagnosis and treatment of erectile dysfunction in patients with type 1 diabetes mellitus. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(3):5-10

Objective. To study clinical characteristics of antipsychotic-induced hyperprolactinemia (AIH) and an impact of AIH on sexual function in patients with mental disorders treated with neuroleptics for a long time. Material and methods. A cross-sectional study of 244 consecutive psychiatric in-patients (F/M=140/104) with mental disorders currently taking antipsychotics was carried out. The patients were screened for serum prolactin, sex hormones and gonadotropin levels. The UKU Side effects rating scale (UKU) was used to assess side-effects. For assessment of sexual dysfunction, the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ) was administered. Results and conclusion. Asymptomatic AIH was found in 16% of females and in 37% of males. AIH caused menstrual disorders (oligomenorrhea and amenorrhea), galactorrhea in females. AIH was associated with libido decrease and life quality impairment due to sexual dysfunctions in patients of both genders. AIH was associated with orgasm delay and vaginal dryness during sexual intercourse in females. In men, AIH was associated with erectile dysfunction. In contrast to pituitary tumor and idiopathic hyperprolactinemia, there was no association between AIH and weight gain and/or obesity, and hypogonadism in patients of both genders.

Keywords:

schizophrenia
psychiatric disorder
antipsychotic
neuroleptics
sexual dysfunctions
galactorrhea
reducing libido
erectile dysfunction
hyperprolactinemia
prolactin
schizophrenia
psychiatric disorder
antipsychotic
neuroleptics
sexual dysfunctions
galactorrhea
reducing libido
erectile dysfunction

Authors:

Iunilaĭnen O.A.

FGBU "ndokrinologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii

Starostina E.G.

FGUZ "Moskovskiĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut (MONIKI) im. M.F. Vladimirskogo"

Dzeranova L.K.

ndokrinologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Kudryashkina G.N.

Psychiatric City Hospital №1, Moscow, Russia

Kesselman L.G.

Psychiatric City Hospital №1, Moscow, Russia

Baranov P.A.

Russian Medical Academy of Postgraduate Education, Moscow, Russia

Dedov I.I.

Endocrinology Research Centre

List of references:

  1. Wieck A, Haddad P. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. The British Journal of Psychiatry. 2003;182:199-204. doi: 10.1192/bjp.182.3.199
  2. Canuso C, Goldstein J, Wojcik J et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 2002;111(1):11-20. doi: 10.1016/S0165-1781(02)00123-3
  3. Smith S, Wheeler M, Murray R et al. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. Journal of Clinical Psychopharmacology. 2002;22(2):109-114. doi:10.1097/00004714-200204000-00002
  4. Johnsen E, Kroken R, Abaza M et al. Antipsychotic-inducedhyperprolactinemia: a cross-sectional survey. J Clin Psychopharmacol. 2008;28(6):686-690. doi: 10.1016/j.schres.2007.12.383
  5. Baptista T, Molina M, Martinez J et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation. Pharmacopsychiatry. 1997;30(6):256-262. doi:10.1055/s-2007-979503
  6. Kinon B, Gilmore J, Liu H et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28(suppl 2):55-68. doi:10.1016/s0306-4530(02)00127-0
  7. Prentice D, Deakin J. Role of neuroleptic drugs and organic mechanisms in the aetiology of menstrual irregularities in schizophrenic women. Schizophrenia Research. 1992;6:114-118. doi: 10.1016/0920-9964(92)90144-t
  8. Eberhard J, Lindstrom E, Holstad M et al. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand. 2007;115(4):268-276. doi: 10.1111/j.1600-0447.2006.00897.x
  9. Neovius M, Eberhard J, Lindström E et al. Weight development in patients treated with risperidone: a 5-year naturalistic study. Acta Psychiatr Scand. 2007;115(4):277-285. doi: 10.1111/j.1600-0447.2006.00899.x
  10. Melkersson K, Berinder K, Hulting A. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses. Neuro Endocrinol Lett. 2011;32(4):428-436.
  11. Baptista T, Lacruz A, Meza T et al. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry. 2001;46(9):829-834.
  12. O’Keane V, Meaney A. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol. 2005;25(1):26-31. doi: 10.1097/01.jcp.0000150223.31007.e0
  13. Kishimoto T, Watanabe K, Shimada N. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69(3):385-391. doi: 10.4088/jcp.v69n0307
  14. Bergemann N, Mundt C, Parzer P. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res. 2005;73(2-3):357-366. doi: 10.1016/j.schres.2004.06.013
  15. Kinon B, Gilmore J, Liu H et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28(suppl 2):55-68. doi: 10.1016/s0306-4530(02)00127-0
  16. Kaneda Y. The impact of prolactin elevation with antipsychoticmedications on subjective quality of life in patients with schizophrenia. Clin Neuropharmacol. 2003;26(4):182-184. doi: 10.1097/00002826-200307000-00006
  17. Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 2011;26(3):130-140. doi: 10.1097/yic.0b013e328341e434
  18. Knegtering H, Boscha R, Casteleina S et al. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology. 2008;33:711—71756. doi: 10.1016/j.psyneuen.2008.02.008
  19. Rettenbacher M, Hofer A, Ebenbichler C et al. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J Clin Psychopharmacol. 2010;30(6):711-715. doi: 10.1097/jcp.0b013e3181faf0e3
  20. Knegtering R, Castelein S, Bous H et al. A Randomized Open-Label Study of the Impact of Quetiapine Versus Risperidone on Sexual Functioning. Journal of Clinical Psychopharmacology. 2004;24(1):56-61. doi: 10.1097/01.jcp.0000106220.36344.04
  21. Johnsen E, Kroken R, Løberg E et al. Sexual Dysfunction and Hyperprolactinemia in Male. Psychotic Inpatients: A Cross-Sectional Study. Advances in Urology. 2011;6-14. doi: 10.1155/2011/686924
  22. Smith SM, O’Keane V, Murray R et al. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J. 2002;63:763-771. doi: 10.1016/s0920-9964(00)90844-2
  23. Mel'nichenko GA, Goncharov NP, Dzeranova LK. i dr. Klinicheskie i laboratornye aspekty issledovanija izoform prolaktina metodom PJeG-precipitacii i ul'trafil'tracii. Problemy Jendokrinologii. 2010;(1):19-25. (In Russ.). doi: 10.14341/probl201056119-25
  24. Nakonezny P, Byerly M, Rush A. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther. 2007;33(3):203-216. doi:10.1080/00926230701267829
  25. Westheide J, Cvetanovska G, Albrecht C et al. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. J Sex Med. 2008;5(12):2816-2826. doi: 10.1111/j.1743-6109.2008.00859.x
  26. Konarzewska B, Wołczyński S, Szulc A et al. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology. 2009;34(1):129-139. doi: 10.1016/j.psyneuen.2008.08.015
  27. Yasui-Furukori N, Fujii A, Sugawara N et al. No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics. Hum Psychopharmacol. 2012;27(1):82-89. doi: 10.1002/hup.1275
  28. Junilajnen OA, Starostina EG, Dzeranova LK. i dr.Jepidemiologicheskie harakteristiki giperprolaktinemii,associirovannoj s priemom nejroleptikov. Sovremennaja terapija v psihiatrii i nevrologii. 2014;(4):4-9. (In Russ.).
  29. Lingjaerde O, Ahlfors U, Bech P et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987;334:1-100. doi: 10.1111/j.1600-0447.1987.tb10566.x
  30. Montejo AL, Rico-Villademoros F. Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. Journal of Sex & Marital Therapy. 2008;34(3):227-239. doi: 10.1080/00926230701866125
  31. Malik P, Kemmler G, Hummer M et al. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol. 2011;31(3):274-280. doi: 10.1097/jcp.0b013e3182199bcc

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.